Showing 240 Results
NPC’s John O’Brien Talks IRA, Drug Pricing, Patient Costs & Access on The Real Chemistry Podcast
In the latest episode of The Real Chemistry Podcast, NPC President and CEO John M. O'Brien spoke with Real Chemistry’s Founder and Chairman, Jim Weiss, on pressing health policy issues.
NPC Evaluates ICER’s Revised 2023 Value Assessment Framework: A Missed Opportunity for Patients and the Field
The Institute for Clinical and Economic Review (ICER) released its revised value assessment framework. NPC outlines key concerns about the framework and the impact on both patients and those who…
Addressing Critical Ambiguities in CMS’s Drug Evaluation Process
With CMS's release of the list of drugs selected for evaluation under the IRA's Medicare Drug Price Negotiation Program, all eyes turn from the list to what’s next in the process. In this blog, NPC's…
Getting Patient Input Right During the IRA Implementation
Important questions remain on how patient input will be incorporated in the IRA process as we approach the release of the list of drugs selected for negotiation.
Commercial coverage of specialty drugs, 2017–2021
New study examines the role of NIH and industry in bringing new treatments into clinical settings.
New Research Finds Commercial Health Plans' Use of Prescriber Requirements Doubled and Use of Step Therapy Increased by More Than 31% for Specialty Drug Coverage
New research co-authored by NPC examines how health plan policies have become more restrictive over time.
NPC Submits Comments to CMS on Medicaid Drug Rebate Program
In this comment letter, NPC weighs in on CMS' proposed rule changes to the Medicaid Drug Rebate Program (MDRP).
NPC Comments on Proposed Changes for ICER Value Assessment Framework
NPC's comments highlight key concerns related to proposed changes to ICER's 2023 Value Assessment Framework.
In 2023, Decision Makers Should Dig into Data About Our Drug Pricing System
In Chain Drug Review, NPC's John O'Brien discusses how 2023 brings renewed imperative to root health policy decisions in evidence.
Shared Decision-Making Makes Sense for Patients and the Bottom Line
If shared decision-making is good for patients, is it good for the bottom line as well? A new study from NPC and Real Chemistry sheds light.
Impact of Shared Decision-Making and Patient Decision Aids on Health Care Cost and Utilization in the US: A Systematic Review
Shared decision-making and patient decision aids may reduce costs or improve utilization but not consistently across settings and diseases, according to a new systemic literature review by…
Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States
Study shows the impact of a more holistic approach to assessing value and how it can help address gaps within conventional value assessment.
Characterizing Health Plan Evidence Review Practices
The study finds that some plans updated the evidence in their coverage policies for specialty medicines more often than others, and the type of evidence plans cited in their coverage policies…
Characterizing health plan evidence review practices: how often, how different, and how comprehensive?
All health care decisions should be evidence-based. Until now, it has been relatively unclear what goes into health plan evidence reviews. How frequently do health plans update their specialty drug…
Health Care Spending Effectiveness: Estimates Suggest that Spending Improved U.S. Health from 1996 to 2016
This research assessed the effectiveness of U.S. health care spending by comparing changes in health outcomes and found that, overall, innovations in health care are creating more cost-effective care…
Commentary: "New York Times Piece on Drug Market Ignores the Data (and Reality)"
NPC's President and CEO John M. O'Brien addresses research using politically expedient shortcuts and the consequences on policy...and patients.
NPC Comments on the Medicare Program's Hospital Inpatient Prospective Payment Systems
NPC's comments to CMS focus on recent proposals related to the transition to National Drug Codes for New Technology Add-on Payments and recommendations regarding payment mechanisms to improve access…
Health Care Spending Guiding Principles
NPC established a set of principles to assess health care spending estimates and policies to ensure alignment with the goals of patient-centered care.